---
layout: default
title: Verapamil
parent: 僅模型預測 (L5)
nav_order: 351
evidence_level: L5
indication_count: 7
---

# Verapamil
{: .fs-9 }

證據等級: **L5** | 預測適應症: **7** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Verapamil: From Cardiovascular Disorders to Obsolete Bundle Branch Block

## One-Sentence Summary

Verapamil is a well-established calcium channel blocker (CCB) used globally for hypertension, cardiac arrhythmias, and angina, but it currently holds no registration in the Philippines.
The TxGNN model's top prediction is **Obsolete Bundle Branch Block** — a deprecated diagnostic category — with **0 clinical trials** and **0 publications** directly supporting this direction.
All seven predicted indications are rated **L5** (model prediction only), and every one carries a **Hold** recommendation; the predictions overall reflect theoretical cardiovascular channel biology rather than actionable clinical opportunity.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not recorded (no Philippines registration) |
| Predicted New Indication | Obsolete Bundle Branch Block |
| TxGNN Prediction Score | 99.62% |
| Evidence Level | L5 |
| Philippines Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current Evidence Pack (DrugBank API data gap). Based on established pharmacological knowledge, Verapamil belongs to the phenylalkylamine class of L-type voltage-gated calcium channel (VGCC) blockers. It acts primarily on cardiac muscle and the atrioventricular (AV) node — slowing AV conduction and reducing ventricular rate — and on vascular smooth muscle, where it produces vasodilation and lowers blood pressure. Its globally documented indications include hypertension, stable and vasospastic angina, supraventricular tachycardia (SVT), and atrial fibrillation/flutter rate control.

The mechanistic logic behind the TxGNN prediction is that both Verapamil and bundle branch block (BBB) involve the cardiac conduction system. Because Verapamil modulates calcium-dependent ion channel activity, the model associates it with a broad class of conduction abnormalities. However, this reasoning has a critical flaw: bundle branch block reflects impaired conduction in the His-Purkinje system (the bundle branches distal to the AV node), whereas Verapamil's primary electrophysiological target is the AV node itself. CCBs do not restore bundle branch conduction and may in fact worsen overall conduction block by additionally suppressing AV node function in an already compromised heart.

Compounding this, the predicted disease name carries the prefix **"obsolete"** — indicating it is a retired ICD classification with no current clinical standing. Any research or regulatory pathway built around this diagnosis would face immediate definitional problems. Taken together, the theoretical mechanistic link is weak and directionally potentially harmful; the obsolete disease label removes any clinical target to pursue.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
All seven TxGNN-predicted indications are L5 (model prediction only, no supporting trials or literature), and the top-ranked prediction targets a clinically obsolete diagnostic category where Verapamil's mechanism is not only unvalidated but potentially contraindicated. The Philippines has zero registered products, which means there is no existing market infrastructure to build on even if a valid repurposing target were identified.

**To proceed, the following is needed:**

- **Clarify the actual repurposing target:** Re-run TxGNN prediction mapping to active (non-obsolete) ICD/OMOP disease codes. Candidates such as pulmonary arterial hypertension (WHO Group 1, vasoreactive subtype) or hypertrophic obstructive cardiomyopathy are better-evidenced indications for CCBs with existing clinical literature.
- **Retrieve Verapamil MOA data from DrugBank API** to enable formal mechanistic scoring (currently blocked by DG002).
- **Retrieve Philippine FDA / PFDA package insert warnings and contraindications** (data gap DG001, Severity: Blocking) before any safety evaluation can proceed.
- **Assess registration pathway:** With 0 current Philippines registrations, first determine whether Verapamil should be submitted for registration for its established indications (hypertension, arrhythmia) before considering any repurposing claim.
- **Run a focused PubMed search** using confirmed Verapamil-specific MeSH terms against any revised target indication to establish a real evidence baseline before re-entering the evaluation pipeline.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

